In 2008, Lupin acquired 60% equity stake in PD, which is involved in distribution of a range of branded, generic prescription medicines and over-the-counter (OTC) products in South
The combined company will be responsible for developing new medicines that address unmet medical needs in critical therapeutic areas and is expected to have combined annual pro forma
Jakavi is the first targeted treatment approved by the EC for these patients in the European Union (EU) who are resistant to or intolerant of hydroxyurea. The European
The MVA Ebola Zaire vaccine candidate is expected to be used in a Phase I clinical trial being supported by a grant from the Wellcome Trust and the
The Canadian group will use Cannigistics’ software and information technology platform to gather, store, analyze and report on the results of the trials. This technology platform will help
The approval allows the new line of products to be distributed in the US into big box retail chain stores as well as facilitate entry into more regulated
Galeterone is being developed to treat castration-resistant prostate cancer (CRPC) that acts by actively disrupting AR signaling, the key driver of prostate cancer growth, via multiple mechanisms of
The supplemental new drug application (sNDA) approval for VIIBRYD expands dosing options available to health care providers when using it to treat MDD in adult patients. The company
The company’s lead drug candidate, ImMucin, targets the less studied Signal Peptide domain of the MUC1 tumor antigen, which harbours key advantages as an anti-MM modality. ImMucin teaches
Valeant’s new offer of $173 a share, is an increase from a bid of $158 per share in cash made this February. The revised share offer, which adds
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.